(-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase

Journal of Neural Transmission, Supplement

Volumn , Issue 48, 1996, Pages 45-59

  Tatton, W G ^a,b   Wadia, J S ^c   Ju, W Y H ^a   Chalmers Redman, R M E ^a,b   Tatton, N A ^a,b  

^a Department of Physiology/Biophysics ^*

^b DALHOUSIE UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MONOAMINE OXIDASE INHIBITOR; NEUROPROTECTIVE AGENT; SELEGILINE; 3,4 DIHYDROXYPHENYLACETIC ACID; AMINE OXIDASE (FLAVIN CONTAINING); NERVE PROTEIN; NOOTROPIC AGENT; PROTEIN SYNTHESIS INHIBITOR;

ANIMAL CELL; APOPTOSIS; CELL CULTURE; CELL GROWTH; DOPAMINERGIC NERVE CELL; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; REVIEW; ALZHEIMER DISEASE; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; GLIA; HUMAN; METABOLISM; MITOCHONDRION; NERVE DEGENERATION; NEURITE; OXIDATIVE STRESS; PARKINSON DISEASE; ULTRASTRUCTURE;

3,4-DIHYDROXYPHENYLACETIC ACID; ALZHEIMER DISEASE; ANIMALS; APOPTOSIS; CELLS, CULTURED; GENE EXPRESSION REGULATION; HUMANS; MITOCHONDRIA; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEURITES; NEUROGLIA; NEURONS; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN SYNTHESIS INHIBITORS; RATS; SELEGILINE;

EID: 0030300164     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-7494-4_5     Document Type: Review

References (14)

1. Amenta F, Bongrani S, Cadel S, Ferrante F, Valsecchi B, Zeng YC (1994) Influence of treatment with L-deprenyl on the structure of the cerebellar. Mech Ageing Dev 75: 157-167
2. Ansari KS, Yu PH, Kruck TP, Tatton WG (1993) Rescue of axotomized immature rat-facial motoneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 13: 4042-4053
3. Ansari KS, Zhang F, Holland DH, Yu PH, Tatton WG (1993) R(-)-deprenyl, not its major metabolites, rescue axotomized immature facial motoneurons. Soc Neurosci Abstr 19: 243
4. Bach AWJ, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan S-E, Seeburg PH, Shih JC (1988) cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci USA 85: 4934-4938
5. Barber AJ, Paterson IA, Gelowitz DL, Voll CL (1993) Deprenyl protects rat hippocampal pyramidal cells from ischemic insult. Soc Neurosci Abstr 19: 1646
6. Ben-Shachar D, Youdim MB (1991) Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J Neurochem 57: 2133-2135
7. Berkelaar M, Clarke DB, Wang YC, Bray GM, Aguayo AJ (1994) Axotomy results in delayed death and apoptosis of retinal ganglion cells in adult rats. J Neurosci 14: 4368-4374
8. Bernardes CF, Meyer-Fernandes JR, Basseres DS, Castilho RF, Vercesi AE (1994) Ca(2+)-dependent permeabilization of the inner mitochondrial membrane by 4,4′-diisothicyanatostilbene-2,2′ disulfonic acid (DIDS). Biochim Biophys Acta 1188: 93-100
9. Berry MD, Scarr E, Zhu MY, Paterson IA, Juorio AV (1994) The effects of administration of monoamine oxidase-B inhibitors on rat striatal neurones response to deprenyl. Br J Pharmacol 113: 1159-1166
10. Biagini G, Zoli M, Fuxe K, Agnati LF (1993) L-Deprenyl increases GFAP immunoreactivity selectively in activated astrocytes in rat brain. NeuroRep 4: 955-958
11. Biagini G, Frasoldati A, Fuxe K, Agnati LF (1994) The concept of astrocyte-kinetic drug in the treatment of neurodegenerative diseases: evidence for L-deprenyl-induced activation of reactive astrocytes. Neurochem 25: 17-22
12. Birkmayer W, Riederer P (1984) Deprenyl prolongs the therapeutic efficacy of combined 1 dopa in parkinsons disease. Adv Neurol 40: 0-89004
13. Birkmayer W, Riederer P, Ambrozi L, Youdim MBH (1977) Implications of combined treatment with "madopar" and L-deprenyl in Parkinson's disease. Lancet i: 439-443
14. Brannan T, Yahr MD (1995) Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Ann Neurol 37: 95-98